# Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

> **NCT01471964** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic
- Non-small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** MLN8237 and Erlotinib

## Key facts

- **NCT ID:** NCT01471964
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-20
- **Primary completion:** 2017-02-07
- **Final completion:** 2018-04-10
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Phase I portion completed. Phase II will open pending amendment approval.
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471964, "Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01471964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*